Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade

The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly influenced by the development of immune checkpoint inhibitors (ICI), but the range of clinical responses observed among patients...

Source: Journal of Experimental and Clinical Cancer Research - March 16, 2024 Category: Cancer & Oncology Authors: Yo-Ting Tsai, Jeffrey Schlom and Renee N. Donahue Tags: Review Source Type: research